Connection

Robert Harrington to Clinical Trials as Topic

This is a "connection" page, showing publications Robert Harrington has written about Clinical Trials as Topic.
Connection Strength

1.140
  1. Assessing research results in the medical literature: trust but verify. JAMA Intern Med. 2013 Jun 24; 173(12):1053-5.
    View in: PubMed
    Score: 0.327
  2. Sharing Data from Cardiovascular Clinical Trials--A Proposal. N Engl J Med. 2016 Aug 04; 375(5):407-9.
    View in: PubMed
    Score: 0.101
  3. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol. 2014 Sep; 176(1):300-2.
    View in: PubMed
    Score: 0.088
  4. Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. Clin Cardiol. 2014 Jun; 37(6):337-42.
    View in: PubMed
    Score: 0.086
  5. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009 Feb 19; 360(8):816-23.
    View in: PubMed
    Score: 0.061
  6. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009 Feb 03; 119(4):597-605.
    View in: PubMed
    Score: 0.060
  7. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May; 5(3):401-12.
    View in: PubMed
    Score: 0.053
  8. MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs. 2005 Nov; 14(11):1435-42.
    View in: PubMed
    Score: 0.048
  9. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005 Mar; 149(3):474-81.
    View in: PubMed
    Score: 0.046
  10. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.
    View in: PubMed
    Score: 0.045
  11. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes. Semin Thromb Hemost. 2004 Dec; 30(6):639-47.
    View in: PubMed
    Score: 0.045
  12. Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation. 2019 09 24; 140(13):1115-1124.
    View in: PubMed
    Score: 0.032
  13. Stanford Cardiovascular Institute. Circ Res. 2019 05 10; 124(10):1420-1424.
    View in: PubMed
    Score: 0.031
  14. Using Digital Health Technology to?Better?Generate Evidence and Deliver?Evidence-Based?Care. J Am Coll Cardiol. 2018 06 12; 71(23):2680-2690.
    View in: PubMed
    Score: 0.029
  15. The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. Am Heart J. 2015 Jun; 169(6):743-50.
    View in: PubMed
    Score: 0.023
  16. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013 Jul 16; 62(3):242-251.
    View in: PubMed
    Score: 0.020
  17. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am Heart J. 2006 Jan; 151(1):16-24.
    View in: PubMed
    Score: 0.012
  18. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005 Mar 01; 95(5):611-4.
    View in: PubMed
    Score: 0.011
  19. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Feb 01; 95(3):383-6.
    View in: PubMed
    Score: 0.011
  20. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003 Jan; 145(1):73-9.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.